FindTrial
Sign In

Lipid-Modifying Therapy (LMT)

DRUG6 trials

Sponsors

Sanofi

Conditions

HypercholesterolaemiaHypercholesterolemia

Phase 3

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
CompletedNCT01507831
SanofiHypercholesterolemia
Start: 2012-01-31End: 2014-11-30Updated: 2015-12-22
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
CompletedNCT01644175
SanofiHypercholesterolemia
Start: 2012-07-31End: 2014-04-30Updated: 2015-11-06
Open Label Study of Long Term Safety Evaluation of Alirocumab
CompletedNCT01954394
SanofiHypercholesterolemia
Start: 2013-12-17End: 2017-06-30Updated: 2018-07-24
Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)
CompletedNCT02107898
SanofiHypercholesterolemia
Start: 2014-03-31End: 2015-09-30Updated: 2016-10-04
Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan
CompletedNCT02289963
SanofiHypercholesterolemia
Start: 2015-01-31End: 2016-04-30Updated: 2017-06-26
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
CompletedNCT02585778
SanofiHypercholesterolaemia
Start: 2015-10-23End: 2017-04-03Updated: 2018-05-17

Related Papers

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study.
2020-08-012 citations
Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia
JAMA Cardiology2020-07-01178 citations
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
2019-11-0926 citations
A subanalysis of Taiwanese patients from ODYSSEY South Korea and Taiwan study evaluating the efficacy and safety of alirocumab.
2019-04-017 citations
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial.
2018-11-3013 citations
Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program.
2018-09-0146 citations
Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia.
2018-08-302 citations
Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DM‐INSULIN</scp> randomized trial
Diabetes Obesity and Metabolism2017-09-14136 citations
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia.
2017-09-0438 citations
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.
2017-03-2419 citations
Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab
Journal of the American College of Cardiology2017-01-30193 citations
Reductions in Atherogenic Lipids and Major Cardiovascular Events
Circulation2016-10-25128 citations
PS165 Alirocumab Efficacy is Independent of Background Statin Type or Dose
Global Heart2016-06-01
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
New England Journal of Medicine2015-03-152260 citations
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
2015-03-13255 citations
Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.
2014-09-2042 citations